Elemental Iron
DrugIron supplementation.
Other names: doses of 25 mg of elemental iron
NCT Number: NCT00655408
This work aims at establishing the effectiveness of weekly doses of ferrous sulfate administered by mothers compared with weekly supplements administered directly by healthcare professionals, to reducing anemia prevalence.
Looking for future studies?
Notify Me6 month–24 month
All sexes
Interventional
Not applicable
Some studies have shown satisfactory results in reducing the prevalence of iron deficiency using weekly doses of ferrous sulfate, thereby avoiding these side effects. This deficiency is the most common nutritional disorder during childhood and does not only affect individuals from developing countries but also those from industrialized nations.
For infants with ages between six and 24 months, iron supplementation is the main treatment for iron deficiency. In this age range the prevalence of anemia is at least 20%. However, studies have shown a low rate of compliance by mothers during the recommended period, which may be caused by a lack of care or, more probably, due to the side effects caused by long-term daily ferrous sulfate supplementation, which include nausea, vomiting, diarrhea, staining of teeth and abdominal pain.
This specific study is randomized clinical trial study, achieved in a government healthcare clinic in Sao Jose do Rio Preto, Sao Paulo, Brazil. This study was carried out using two intervention groups. All children received 12 weekly doses of 25 mg of elemental iron, either administered in the government healthcare clinic or at the children's home.
The study showed treatment compliance in both groups. Prevalence of anemia for all children was 75% at the beginning of supplementation and 46.3% at the end of the period (p < 0.0005). Reduction rate for anemic children was 38.3%. Average increases in hemoglobin concentration levels were 0.75 g/dL and 0.65 g/dL, respectively, for home interventions and healthcare clinic administration (p < 0.00005).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Iron supplementation.
Other names: doses of 25 mg of elemental iron
Time frame: assessed at the before of the treatment period
Time frame: assessed after 12 weekly with iron supplement
Looking for future studies?
Notify MeSao Jose do Rio Preto Medical School
Other
Iron-Deficiency Anemia in Infants: Comparative Study of Two Weekly Supplement Programs
Acronym: IDA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03459287
Anemia, Hematologic Diseases
Los Angeles, California, United States
View Trial DetailsNCT03558464
Anemia, Growth Disorders
Kakamega, Kenya
View Trial DetailsNCT05889052
Anemia, Hematologic Diseases
Soa and Mbankomo, Cameroon
View Trial DetailsNCT05856357
Anemia, Hematologic Diseases
Séguéla, Côte d’Ivoire
View Trial Details